Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
/ 2 items
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
Oppenheimer initiates coverage of Coherus Oncology with an Outperform rating and a $10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026.